<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="163">
  <stage>Registered</stage>
  <submitdate>10/08/2005</submitdate>
  <approvaldate>15/08/2005</approvaldate>
  <actrnumber>ACTRN12605000145606</actrnumber>
  <trial_identification>
    <studytitle>Repetitive Transcranial Magnetic Stimulation (rTMS) in the treatment of depression.</studytitle>
    <scientifictitle>Repetitive Transcranial Magnetic Stimulation (rTMS) in the treatment of depression, assessed with HAMD-21 over a four week period.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Depression.</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Active control comparison of two different rTMS parameter sets, over the left dorsolateral prefrontal cortex. Additional to current medication. 
a) 10Hz frequency. 100% MT.
b) Variable frequency dependent upon background activity. 100% MT.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rating scales for depression for clinicians (Hamilton 21 point).</outcome>
      <timepoint>Before and after four weeks of treatment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Rating scales for depression, self administered (Beck Depression Inventory).</outcome>
      <timepoint>Before and after four weeks of treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>EEG recordings and a battery of cognition tests will also be administered.</outcome>
      <timepoint>Prior to treatment, after 4 weeks treatment, and 6 months post treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria />
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A random sequence was generated prior to recruitment, and used to allocate from a central station by phone. Staff involved in intervention or assessment have no access to the sequence.</concealment>
    <sequence>A computer package (SPSS for Windows11.5) randomly selected from 200 cases. Participants assigned in sequence of recruitment.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>20/08/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Centre for Clinical Research in Neuropsychiatry</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>WA Health Department</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>North Metropolitan Area Health Service</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to evaluate the therapeutic application of repetitive transcranial magnetic stimulation (rTMS) as a potential treatment for depression.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Human Research Ethics Committee,North Metropolitan Health Service, Perth</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Joseph Lee</name>
      <address>Graylands Hospital 
Brockway Road
Mount Claremont WA 6010</address>
      <phone>+61 8 93476801</phone>
      <fax>+61 8 93852701</fax>
      <email>Joseph.Lee@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Greg Price</name>
      <address>Centre for Clinical Research in Neuropsychiatry
John XXIII Avenue
Mount Claremont WA 6010</address>
      <phone>+61 8 93476493</phone>
      <fax>+61 8 93845128</fax>
      <email>gregp@ccrn.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>